GGrantIndex
Sort

48,018 grants matching immunotherapy

CENTRAL TOLERANCE BLOCKADE TO AUGMENT CHECKPOINT IMMUNOTHERAPY IN MELANOMA

$547,185
University Of North Carolina At Chapel Hill · · FY2015 · Department of the Army

Loss of NF1 drives hormone dependent mammary carcinogenesis in a rat model with intact immune system

$547,183
Deeann Wallis-Schultz · University Of Alabama At Birmingham · R01 · FY2025 · CA

Loss of NF1 drives hormone dependent mammary carcinogenesis in a rat model with intact immune system

$547,183
Deeann Wallis-Schultz · University Of Alabama At Birmingham · R01 · FY2022 · CA

Pro-tumorigenic functions of human DNA polymerases eta and kappa during genome duplication under physiological replication stress conditions

$547,143
Kristin A Eckert · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2023 · CA

Antibodies, B cells and resistance to human cryptococcosis

$547,115
Liise-Anne Pirofski · Albert Einstein College Of Medicine · R01 · FY2023 · AI

Targeting the vasculature to enhance anti-tumor immunity

$547,081
Andrew Carl Dudley · University Of Virginia · R01 · FY2025 · CA

Discovery of Drugs, Targets, and Target Strategies for Immunotherapy of CLL

$547,078
Christoph Rader · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA

Role of heat shock transcription factor HSF1 in tumorigenesis

$547,029
Nahid F Mivechi · Augusta University · R01 · FY2022 · CA

Optimization of small molecule integrin activators to enhance cord blood transplant

$547,028
Peter Vanderslice · Texas Heart Institute · R33 · FY2022 · HL

Optimization of small molecule integrin activators to enhance cord blood transplant

$547,028
Peter Vanderslice · Texas Heart Institute · R33 · FY2023 · HL

A robust platform for multiplexed, subcellular proteomic imaging in human tissue

$547,000
Robert Michael Angelo · Stanford University · UH3 · FY2021 · CA

Local immune tolerance in the large intestine mediated by GPR15

$546,983
Sangwon Vincent Kim · Thomas Jefferson University · R01 · FY2020 · AI

Local immune tolerance in the large intestine mediated by GPR15

$546,983
Sangwon Vincent Kim · Thomas Jefferson University · R01 · FY2021 · AI

Local immune tolerance in the large intestine mediated by GPR15

$546,983
Sangwon Vincent Kim · Thomas Jefferson University · R01 · FY2024 · AI

Local immune tolerance in the large intestine mediated by GPR15

$546,983
Sangwon Vincent Kim · Thomas Jefferson University · R01 · FY2022 · AI

Local immune tolerance in the large intestine mediated by GPR15

$546,983
Sangwon Vincent Kim · Thomas Jefferson University · R01 · FY2023 · AI

Definition of Immune Infiltrate Phenotype and DNA Damage Response Deficits Across Diverse Murine Mammary Carcinomas

$546,808
Mary Helen Barcellos-Hoff · University Of California, San Francisco · R01 · FY2020 · CA

Project 1- Elucidating oncogenic KRAS in PDAC cell signaling, resistance and immunity

$546,753
Ronald Anthony Depinho · University Of Tx Md Anderson Can Ctr · P01 · FY2023 · CA

Project 3-Cancer cell interaction with oncogenic type 1 collagen in PDAC

$546,752
Raghu Kalluri · University Of Tx Md Anderson Can Ctr · P01 · FY2023 · CA

Project 1- Elucidating oncogenic KRAS in PDAC cell signaling, resistance and immunity

$546,751
Ronald Anthony Depinho · University Of Tx Md Anderson Can Ctr · P01 · FY2021 · CA

Project 3-Cancer cell interaction with oncogenic type 1 collagen in PDAC

$546,750
Raghu Kalluri · University Of Tx Md Anderson Can Ctr · P01 · FY2021 · CA

Imaging the effects of transcranial alternatingcurrent stimulation in an experimental model of Alzheimer's Disease

$546,676
Bojana Stefanovic · Sunnybrook Research Institute · R01 · FY2025 · AG

Targeting iRhom to Improve Colon Cancer Immunochemotherapy

$546,625
Song Li · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · CA

An urinary drug disposing approach for treatment of bladder Cancer

$546,617
Benedict Shek Hang Law · Weill Medical Coll Of Cornell Univ · R01 · FY2025 · CA

New Materials to Deliver mRNA: Applications in Cancer Immunotherapy

$546,613
Robert M. Waymouth · Stanford University · R01 · FY2020 · CA